Response to Letter to the Editor From Zhang et al: “Cabozantinib Plus Ipilimumab/Nivolumab in Patients with Previously Treated Advanced Differentiated Thyroid Cancer”
The Journal of Clinical Endocrinology & Metabolism | April 4, 2025 | Volume: 110 | Issue: 7 | Pages: e2425-e2426
10.1210/clinem/dgaf221
| PMID 40184489